Loading…
PATADAY is a brand name for Olopatadine, supplied as a solution. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: PATADAY® (olopatadine hydrochloride ophthalmic solution) is indicated for: • the treatment of ocular itching associated with seasonal allergic conjunctivitis. 1.1 Pediatrics Paediatrics (<18 years): The effectiveness of PATADAY has not been established in paediatric patients <18 years of age. No overall difference in…
Verbatim from this product's HC label. Tap a section to expand.
1 Dosing Considerations No special dosage considerations are necessary for PATADAY. 2 Recommended Dose and Dosage Adjustment The recommended dose is one drop in each affected eye once a day. No dosage adjustment is required in hepatic or renal impairment.
5 Missed Dose If a dose is missed, a single drop should be taken as soon as possible before reverting to regular routine. Do not use a double dose to make up for the one missed. Pataday® (Olopatadine Hydrochloride) Product Monograph Page 6 of 23
1 Adverse Reaction Overview In clinical trials involving 1137 patients dosed with long-term ophthalmic topical therapy, PATADAY was administered once-daily for 4 to 12 weeks. 4%). No serious adverse drug reactions related to PATADAY were reported in the clinical trials.
2 Clinical Trial Adverse Reactions Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug.
Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use. No treatment-related adverse drug reactions occurred at an incidence ≥ 1%. 1%) are presented below.
4 million units of PATADAY have been sold worldwide. 0007%. No post-market reports of serious adverse reactions have been received to date. The most frequent events reported being eye irritation, ocular hyperaemia, eye pain and vision blurred.
There were no new major findings bearing on the established overall safety profile of PATADAY. Other events include dizziness, eye discharge, punctate keratitis, keratitis, erythema of eyelid, dermatitis contact, fatigue, hypersensitivity, ocular discomfort, lacrimation increased and nausea.
General For topical ocular use only. Not for injection or oral use. 2% w/v Benzalkonium chloride (preservative), disodium phosphate, edetate disodium, hydrochloric acid and/or sodium hydroxide (to adjust pH), povidone, purified water, sodium chloride.
Pataday® (Olopatadine Hydrochloride) Product Monograph Page 7 of 23 taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use. Driving and Operating Machinery Olopatadine is a non-sedating anti-histamine.
Temporary blurred vision or other visual disturbances, after the use of PATADAY, may affect the ability to drive or use machines. If blurred vision occurs after instillation, patients must wait until vision clears before driving or using machinery.
Ophthalmologic Patients should be advised not to wear contact lenses if their eye(s) are red. PATADAY should not be used to treat contact lens related irritation. The preservative in PATADAY, benzalkonium chloride, may cause eye irritation and is known to discolour soft contact lenses.
Contact with soft contact lenses should be avoided. Patients must be instructed to remove contact lenses prior to application of PATADAY, and wait at least 15 minutes before they insert their contact lenses. If using other eye drops, patients should wait at least five minutes between putting in PATADAY and the other drops.
Eye ointments should be applied last.
Reproductive Health:
Female and Male Potential • Fertility Studies have not been performed to evaluate the effect of topical ocular administration of olopatadine on human fertility. 1 Pregnant Women There are no adequate and well controlled studies in pregnant women.
Studies in animals with olopatadine have shown reproductive toxicity following systemic administration considered sufficiently in excess of the maximum human exposure. Olopatadine was found not to be teratogenic in rats and rabbits at oral doses >90,000 and >60,000 times the maximum recommended ocular human use level, respectively (see 16 NON-CLINICAL TOXICOLOGY, Reproductive and Developmental Toxicology).
Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING section of the Product Monograph.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Olopatadine in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Because animal studies are not always predictive of human responses, PATADAY should be used in pregnant women only if the potential benefit to the mother justifies the potential risk to the embryo or fetus. 2 Breast-feeding Olopatadine has been identified in the milk of nursing rats following oral administration.
It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in human breast milk. Nevertheless, caution should be exercised when PATADAY is administered to a nursing mother.
3 Pediatrics Paediatrics (<18 years): Effectiveness in paediatric patients has not been established. No overall difference in safety has been observed between paediatric and adult patients. 4 Geriatrics: No overall differences in safety and effectiveness have been observed between elderly and other adult patients.